As shown in Figure 3F, resmetirom treatment effectively decreased lipid accumulation in the NAFLD/NASH cell model, while RGS5 knockdown markedly impaired the role of resmetirom. Here, RGS5 is linked to metabolic dysfunction-associated steatotic liver disease.